Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
November 7, 2018 8:00 AM ESTObtained FDA and EMA Approvals of ONPATTRO (patisiran) the First-Ever RNAi Therapeutic and Launched in U.S. and EU
Received 125 U.S. Patient Start Forms in First Seven Weeks of ONPATTRO Launch
Reported Positive Topline Interim Analysis Results from ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyrias
Advanced Lumasiran into ILLUMINATE Phase 3 Program
Maintained Strong Balance Sheet with $1.27 Billion in Cash and Expects to End 2018 with Approximately $1.0 Billion in Cash
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
